Physician profile
Giles R Scuderi
NPI 1639113863
$10,654,746.30
in general payments reported to CMS, 2019-2025
10 companies · $52K in 2025
The $52K reported for 2025 was more than what 95% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.0M · 2020: $1.1M · 2021: $1.4M · 2022: $1.4M · 2023: $5.7M · 2024: $63K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $5.6M · Education: $88K · Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $8,609 · Food and Beverage: $4,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $5,638,599.52 |
| Education | $87,875.00 |
| Consulting Fee | $30,590.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,200.00 |
| Travel and Lodging | $8,609.30 |
| Food and Beverage | $4,877.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $10,600,668.45 | 2019-2025 | Persona, Avenir, Arcos |
| Kci USA, INC. | $27,089.86 | 2019-2023 | Abthera Advance, Promogran Prisma, Prevena |
| Solventum Corporation | $17,150.00 | 2024-2025 | Prevena, Spoton, 3m Ioban |
| Convatec INC. | $7,425.00 | 2020 | |
| Canary Medical USA LLC | $1,675.17 | 2022-2023 | |
| Smith+Nephew, INC. | $308.03 | 2019 | |
| Pacira Therapeutics, INC. | $247.18 | 2019 | |
| Stryker Corporation | $169.16 | 2024 | Mako, Triathlon |
| Depuy Synthes Sales INC. | $13.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giles Scuderi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.